Mifoglame (Sitagliptin)

Sitagliptin, the active ingredient in Mifoglame, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral formulation for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Mifoglame as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifoglame (sitagliptin) belongs to the DPP‑4 inhibitor class and is employed in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion and reducing glucagon release. - Monotherapy in type 2 diabetes: can be used alone when diet and exercise are insufficient. - Combination therapy: added to metformin or other oral agents to achieve target blood glucose levels.

Sitagliptin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory infection: cough, sore throat, or congestion. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Hepatic enzyme elevation: increased ALT/AST levels. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.

Before initiating sitagliptin therapy, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: use with caution in moderate to severe liver disease. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia. - History of pancreatitis: avoid use and observe for symptoms. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Sitagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Strong DPP‑4 inhibitors (e.g., saxagliptin): additive effect, not recommended.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma concentrations. - Diuretics: may affect glucose control, requiring monitoring. - ACE inhibitors: potential for altered renal function, necessitating observation.